Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $36.2 million.

  • BioXcel Therapeutics' Cash & Equivalents fell 1042.66% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.2 million, marking a year-over-year decrease of 1042.66%. This contributed to the annual value of $29.9 million for FY2024, which is 5422.64% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Cash & Equivalents stood at $36.2 million for Q3 2025, which was down 1042.66% from $17.4 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Cash & Equivalents high stood at $233.5 million for Q2 2022, and its period low was $17.4 million during Q2 2025.
  • Its 4-year average for Cash & Equivalents is $106.2 million, with a median of $74.1 million in 2024.
  • Data for BioXcel Therapeutics' Cash & Equivalents shows a peak YoY increase of 1042.66% (in 2025) and a maximum YoY decrease of 6901.6% (in 2025) over the last 5 years.
  • BioXcel Therapeutics' Cash & Equivalents (Quarter) stood at $193.7 million in 2022, then plummeted by 66.33% to $65.2 million in 2023, then crashed by 54.23% to $29.9 million in 2024, then grew by 21.18% to $36.2 million in 2025.
  • Its Cash & Equivalents stands at $36.2 million for Q3 2025, versus $17.4 million for Q2 2025 and $31.0 million for Q1 2025.